Loss of DLX3 tumor suppressive function promotes progression of SCC through EGFR-ERBB2 pathway.

Emerging evidence suggests that homeoproteins can act as modulators of tumor initiation and progression. Our findings show that loss of DLX3 tumor suppressive function acts as a tumor promoter through regulation of ERBB2 and EGFR signaling and also support an important inhibitory role of DLX3 in skin cancer promotion and progression, that may potentially be used as a promising prognostic marker. Overall design: This dataset includes RNA-seq data from five tumors and, skin tissues from three treated Wild Type and DLX3cKO mice. Molecular evaluation of the DLX3cKO tumor-permissive properties was done by performing RNAseq on tumors, DLX3cKO unaffected whole skin, and WT skin from the triple dose DMBA-only protocol. We compared differentially expressed genes (DEG) from DLX3cKO/WT treated skins against Tumor/DLX3cKO skin.